Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021

News
Video

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

CancerNetwork® sat down with Paolo Ghia, MD, from the Universita Università Vita-Salute San Raffaele, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the CAPTIVATE trial (NCT02910583) examining the chemotherapy-free regimen of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL). With the all-oral therapy regimen, patients experienced promising progression-free survival and overall survival.

Transcript:

This [regimen] is really opening a new way of treating patients with chronic lymphocytic leukemia, because so far we are used to continuing treatment, which [has] revolutionized the treatment in CLL. With the advent of oral therapies, [patients] indeed experienced increases in the progression-free survival and overall survival. Of course, having a fixed-duration treatment might be very beneficial for our patient because that would allow [us] to stop the treatment after a number of months, preventing the long-term adverse events, but also the possibility of the occurrence gene mutations and therefore resistance to the drugs.

Reference

Ghia P, Allan J, Siddiqi T et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 39;2021(suppl 15):7501. doi: 10.1200/JCO.2021.39.15_suppl.7501

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Related Content